结直肠癌同时合并腹水的临床病理特点及其预后分析

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (50 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the prognostic results of clinicopathological data in patients with colorectal cancer combined with ascites and analyze the prognosis. Methods The clinicopathological and follow up study data of 139 patients combined with ascites and 400 patients without ascites between October 1999 and January 2005 in our department were retrospectively analyzed and evaluated the prognosis between them by SPSS 19.0. Results Single factor analysis revealed that the prognostic of patients combined with ascites were associated with the factors,such as intestinal obstruction,pelvic metastatic nodal,peritoneal implantation,liver metastasis,viscera invasion,tumor location,radical degrees,tumor type,depth of infiltration,and histological classification（P＜0.01）.Peritoneal implantation（OR＝1.781,95％CI＝1.131-2.804）,pelvic metastatic nodal（OR＝3.211,95％CI＝1.196-8.623）,liver metastasis（OR＝3.127,95％CI＝1.777-5.502）,depth of infiltration（OR＝2.789,95％CI＝1.015-7.665）were of important factors in radical prostatectomy of colorectal cancer combined with ascites by binary Logistic analysis;survival analysis revealed that overall survival were different in whether colorectal cancer combined with ascites（1,3,5,10 year of survival rate respectively:80％,67％,60％, 41％vs 58％,48％,38％,27％）and resection and lymphnodenectomy contribute to improve overall survival（P＜0.05）. Conclusion Patients with colorectal cancer combined with ascites indicate poor prognostic results.Patients with colorectal cancer combined with ascites underwent dissection and lymphnodenectomy can significantly improve the survival rates.

Key words： Colorectal cancer Ascites Clinicopathology Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Hong-xu
	ZHANG Ji-dong
	LI Dong-ping
	LU Yan-xing
	LI Rui

Cite this article:

WANG Hong-xu,ZHANG Ji-dong,LI Dong-ping, et al. Clinicopathological features and prognosis of colorectal cancer with ascites[J]. 中国当代医药, 2016, 23(2): 42-46.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I2/42

[2]	Ringenberg QS，Doll DC，Loy TS，et al.Malignant ascites of unknown origin[J].Cancer，1989，64（31）：753-755.
[3]	张秀春.173例恶性腹水病因及临床特点分析[J].中国当代医药，2010，17（21）：173-174.
[4]	Garrison RN，Galloway RH，Heuser LS.Mechanisms of malignant ascites production[J].J Surg Res，1987，42（8）：126-132.
[5]	Olopade OI，Ultmann JE.Malignant effusions[J].CA Cancer J Clin，1991，41（3）：166-179.
[1]	Lu J，Li XF，Kong LX，et al.Expression and significance of cyclooxygenase-2 mRNA in benign and malignant ascites[J]. World J Gastroenterol，2013，19（40）：6883-6887.
[6]	杨国樑，郑树.消化系统恶性肿瘤治疗学[M].北京：科学出版社，2000：183-259.
[7]	黄小杏，黄世勇，谢伟，等.150例结直肠癌浸润深度与淋巴结转移情况的临床病理研究[J].中国当代医药，2013，20（33）：4-6，10.
[8]	Tamura S，Miki H，Okada K，et al.Pilot study of a combination of S1and paclitaxel for patients with peritoneal metastasis from gastric cancer[J].Gastric Cancer，2010，13 （2）：101-108.
[9]	Kobayashi M，Sakamoto J，Namikawa T，et al.Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients[J].World J Gastroenterol，2006，12（12）：1412-1415.
[10]	Yamao T，Shimada Y，Shirao K，et al.PhaseⅡstudy of sequential methotrexate and 5-Fluorouracil chemothera-py against peritoneally disseminated gastric cancer with malignant ascites：a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group，JCOG 9603 Trail[J].Jpn J Clin Oncol，2004，34（32）：316-322.
[11]	Tahara M，Ohtsu A，Boku N，et al.Sequential methotrexate and 5-Fluorouracil therapy for gastric cancer patients with peritoneal dissemination：a retrospective study [J]. Gastric Cancer，2001，4（9）：212-218.
[12]	Haruhiko I，Koji O，Junichi S，et al.Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions：a multicenter phase Ⅱtrial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer[J].Gastric Cancer，2011，14（7）：81-90.
[13]	Masako I，Takashi K，Narikazu B，et al.Efficacy of sequential methotrexate and 5-Fluorouracil（MTX/5FU）in improving oral intake in patients with advanced gastric cancer with[J].Gastric Cancer，2009，12（8）：153-157.
[14]	尚红娟，黄龙璋，邓泽锋，等.替吉奥联合腹腔化疗方案治疗胃癌腹水的临床效果观察[J].中国当代医药，2014，21（25）：99-101.
[15]	齐瑾，郑玉军，王明吉.洛铂腹腔灌注联合替吉奥治疗晚期胃癌合并腹水的临床观察[J].中国当代医药，2014，21（14）：63-66.
[16]	张超，韩振国.化疗联合中药治疗在结直肠癌术后的临床效果观察[J].中国当代医药，2015，22（14）：135-138，141.
[17]	韩庆海.结直肠癌肝转移的治疗[J].中国当代医药，2011，18（2）：11-13.
[18]	朱金水，陈尼维，陈维雄.腹腔免疫化疗治疗结直肠癌术后癌性腹水近期疗效[J].肿瘤，2000，20（3）：216.
[19]	陈祖龙，吴印兵，崔书中，等.腹腔热灌注化疗联合静脉化疗治疗恶性腹水的临床疗效观察[J].实用医学杂志，2014，30（18）：2950-2952.
[20]	Cui S，Ba M，Tang Y，et al.Bultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites[J].Oncol Rep，2012，28（4）：1325-1331.